Gilead’s $4.9 Bln Deal Shows Regular Death Goes On
March 03, 2020 at 04:40 AM EST
While the world is riveted by the rapid spread of Covid-19, Gilead Sciences’ (GILD) $4.9 billion deal for cancer startup Forty Seven shows that regular death goes on.
